Plasma Paraoxonase-1, Oxidized Low-Density Lipoprotein and Lipid Peroxidation Levels in Gout Patients
- 195 Downloads
Gout patients have a high incidence of atherosclerotic coronary heart disease. Low serum paraoxonase (PON) activity is considered a risk factor for atherosclerosis. The relationships among paraoxonase-1 (PON1) activity, oxidative stress parameters, and atherosclerosis in gout is not known. Therefore, we determined the plasma levels of malondialdehyde (MDA), oxidized low-density lipoprotein (Ox-LDL), and activities of PON1/superoxide dismutase (SOD) activities in 49 gout patients (mean age 44.2 ± 7.0 years) and 42 healthy, age-matched controls (mean age 45.0 ± 9.3 years). PON1 was measured spectrophotometrically, MDA by thiobarbituric acid method, SOD by Griess reaction, and Ox-LDL by sandwich ELISA. Lipid and other biochemical parameters were determined by routine laboratory methods. In gout patients, PON1/SOD activities and MDA/Ox-LDL levels were 131.3 ± 25.3/75.3 ± 28.9 kU l−1 and 6.12 ± 1.67 nmol ml−1/690.1 ± 180.2 μg l−1, respectively. In controls, these were 172.5 ± 27.8/94.0 ± 26.3 kU l−1 and 4.10 ± 1.25 nmol ml−1/452.3 ± 152.1 μg l−1, respectively. Thus, in gout patients, there was a significant decrease in PON1 (P < 0.01) and SOD (P < 0.05) activities, and an increase in MDA (P < 0.01) and Ox-LDL (P < 0.01) levels compared with controls. PON1 activity correlated positively with SOD (P < 0.05), and negatively with MDA (P < 0.01) and Ox-LDL (P < 0.01). These results suggest that gout patients were in a state of oxidative stress and the protective effects of HDL against atherosclerosis maybe dependent on PON1 activity. These findings may explain in part the reported increase in cardiovascular mortality in gout patients.
KeywordsGout Paraoxonase-1 Oxidized low-density lipoprotein Lipid peroxidation
The authors thank the Department of Health of Sichuan Province for the financial support (Grant #20090143), for this study.
- 6.Krishnan, E. (2010). Inflammation, oxidative stress and lipids: The risk triad for atherosclerosis in gout. Rheumatology, 3, 1–10.Google Scholar
- 14.Beckman, J. S., & Koppenol, W. H. (1996). Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and the ugly. American Journal of Physiology, 271, C3424–3437.Google Scholar
- 16.Ferre, N., Camps, J., Prats, E., et al. (2008). Serum paraoxonase activity: A new additional test for the improved evaluation of chronic liver damage. Clinical Chemistry, 48, 261–268.Google Scholar
- 19.Mackness, B., Hunt, R., Durrington, P. N., & Mackness, M. I. (1997). Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 17, 1233–1238.CrossRefPubMedGoogle Scholar
- 22.Inokuchi, T., Moriwaki, Y., Tsutsui, H., et al. (2006). Plasma interleukin (IL)-18 (interferon-gamma-inducing factor) and other inflammatory cytokines in patients with gouty arthritis and monosodium urate monohydrate crystal-induced secretion of IL-18. Cytokine, 33, 21–27.CrossRefPubMedGoogle Scholar
- 25.Deakin, S., Leviev, I., Gomaraschi, M., Calabresi, L., Franceschini, G., & James, R. W. (2002). Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. The Journal of Biological Chemistry, 277, 4301–4308.CrossRefPubMedGoogle Scholar